Phase 3 study of denosumab for the treatment of bone metastases associated with breast cancer
Amgen announced that its Phase 3 trial comparing denosumab to Zometa (zoledronic acid, from Novartis) in the treatment of bone metastases in patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.